GC Biopharma Corp

Quick facts

Phase 3 pipeline

• GC5107 · Endocrinology
  GC5107 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon release to lower blood glucose levels.
• MG1111 (Barycela inj.) · Virology / Immunology
  MG1111 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.

Phase 1 pipeline

• GC1123
• GC1130A
• GC3111B
• MG1111

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• GC Biopharma Corp portfolio CI brief
• GC Biopharma Corp pipeline updates RSS